

Eric Eldering

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7449767/publications.pdf>

Version: 2024-02-01

135
papers

5,331
citations

76326

40
h-index

88630

70
g-index

137
all docs

137
docs citations

137
times ranked

7849
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 2590-2594.	1.4	493
2	CD20 deficiency in humans results in impaired T cell-independent antibody responses. <i>Journal of Clinical Investigation</i> , 2010, 120, 214-222.	8.2	324
3	miR-34a as part of the resistance network in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 3801-3808.	1.4	258
4	Histone Deacetylase Inhibitors Suppress Inflammatory Activation of Rheumatoid Arthritis Patient Synovial Macrophages and Tissue. <i>Journal of Immunology</i> , 2010, 184, 2718-2728.	0.8	208
5	The Noxa/Mcl-1 Axis Regulates Susceptibility to Apoptosis under Glucose Limitation in Dividing T Cells. <i>Immunity</i> , 2006, 24, 703-716.	14.3	161
6	Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. <i>Blood</i> , 2007, 109, 1660-1668.	1.4	147
7	APRIL promotes B-1 cell-associated neoplasm. <i>Cancer Cell</i> , 2004, 6, 399-408.	16.8	144
8	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	1.6	141
9	Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. <i>Nucleic Acids Research</i> , 2003, 31, 153e-153.	14.5	139
10	The Costimulatory Molecule CD27 Maintains Clonally Diverse CD8+ T Cell Responses of Low Antigen Affinity to Protect against Viral Variants. <i>Immunity</i> , 2011, 35, 97-108.	14.3	121
11	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. <i>Blood</i> , 2019, 134, 44-58.	1.4	118
12	IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. <i>Blood</i> , 2013, 122, 3010-3019.	1.4	107
13	CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. <i>International Immunology</i> , 2007, 19, 713-718.	4.0	104
14	Enhanced formation and survival of CD4 ⁺ CD25 ^{hi} Foxp3 ⁺ T-cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 788-801.	1.3	100
15	Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. <i>Haematologica</i> , 2015, 100, e302-6.	3.5	100
16	COOH-terminal Substitutions in the Serpin C1 Inhibitor That Cause Loop Overinsertion and Subsequent Multimerization. <i>Journal of Biological Chemistry</i> , 1995, 270, 2579-2587.	3.4	94
17	Blimp-1 homolog Hobit identifies effector-type lymphocytes in humans. <i>European Journal of Immunology</i> , 2015, 45, 2945-2958.	2.9	94
18	Modulation of Contact System Proteases by Glycosaminoglycans. <i>Journal of Biological Chemistry</i> , 1996, 271, 12913-12918.	3.4	89

#	ARTICLE	IF	CITATIONS
19	Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2012, 18, 487-498.	7.0	88
20	Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. <i>Blood Advances</i> , 2019, 3, 2642-2652.	5.2	79
21	Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones. <i>Immunity</i> , 2010, 32, 754-765.	14.3	78
22	Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. <i>FEBS Journal</i> , 2002, 269, 2546-2556.	0.2	76
23	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2010, 95, 1510-1518.	3.5	73
24	Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 442-451.	2.8	70
25	C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. <i>Nature Genetics</i> , 1992, 1, 354-358.	21.4	68
26	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <i>Blood</i> , 2020, 136, 2918-2926.	1.4	67
27	CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. <i>British Journal of Haematology</i> , 2004, 127, 404-415.	2.5	65
28	Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9932-9941.	7.1	64
29	Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 767-779.	3.4	62
30	TR3 Orphan Receptor Is Expressed in Vascular Endothelial Cells and Mediates Cell Cycle Arrest. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1535-1540.	2.4	61
31	Notch controls the magnitude of T helper cell responses by promoting cellular longevity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9041-9046.	7.1	54
32	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 717-724.	1.4	53
33	<i>In vivo</i> Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. <i>Cancer Research</i> , 2008, 68, 10137-10144.	0.9	52
34	Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2011, 16, 708-721.	4.9	52
35	Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. <i>Haematologica</i> , 2017, 102, 1469-1476.	3.5	52
36	High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-1). <i>Journal of Molecular Biology</i> , 2000, 301, 1135-1147.	4.2	50

#	ARTICLE	IF	CITATIONS
37	Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. <i>Blood</i> , 2011, 117, 6856-6865.	1.4	47
38	CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. <i>Blood</i> , 2011, 118, 5178-5188.	1.4	44
39	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 390-402.	7.2	44
40	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. <i>Haematologica</i> , 2020, 106, 87-97.	3.5	43
41	Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. <i>Journal of Molecular Biology</i> , 2001, 305, 773-783.	4.2	41
42	Regulation of Bcl-XL by non-canonical NF- κ B in the context of CD40-induced drug resistance in CLL. <i>Cell Death and Differentiation</i> , 2021, 28, 1658-1668.	11.2	41
43	Apoptosis via the B cell antigen receptor requires Bax translocation and involves mitochondrial depolarization, cytochrome C release, and caspase-9 activation. <i>European Journal of Immunology</i> , 2004, 34, 1950-1960.	2.9	40
44	The Functional Integrity of the Serpin Domain of C1-inhibitor Depends on the Unique N-terminal Domain, as Revealed by a Pathological Mutant. <i>Journal of Biological Chemistry</i> , 2003, 278, 29463-29470.	3.4	39
45	Improving CLL $\text{V}\lambda$ cell fitness for cellular therapy by ex vivo activation and ibrutinib. <i>Blood</i> , 2018, 132, 2260-2272.	1.4	39
46	Requirement for Aspartate-cleaved Bid in Apoptosis Signaling by DNA-damaging Anti-cancer Regimens. <i>Journal of Biological Chemistry</i> , 2004, 279, 28771-28780.	3.4	37
47	DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. <i>Blood</i> , 2011, 117, 1622-1632.	1.4	35
48	A role for HVEM, but not lymphotoxin receptor, in LIGHT-induced tumor cell death and chemokine production. <i>European Journal of Immunology</i> , 2009, 39, 2502-2514.	2.9	33
49	BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. <i>Blood</i> , 2012, 119, 1440-1449.	1.4	33
50	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?. <i>Frontiers in Oncology</i> , 2020, 10, 592205.	2.8	31
51	Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity. <i>PLoS Biology</i> , 2020, 18, e3000648.	5.6	31
52	Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. <i>Cell Death and Differentiation</i> , 2017, 24, 111-119.	11.2	29
53	Characterization of C1 Inhibitor-Ta. <i>Journal of Biological Chemistry</i> , 1996, 271, 24307-24312.	3.4	27
54	WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 1-6.	2.1	26

#	ARTICLE	IF	CITATIONS
55	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. <i>Leukemia Research</i> , 2014, 38, 34-41.	0.8	24
56	Pro-Apoptotic Protein Noxa Regulates Memory T Cell Population Size and Protects against Lethal Immunopathology. <i>Journal of Immunology</i> , 2013, 190, 1180-1191.	0.8	22
57	CD70-Driven Costimulation Induces Survival or Fas-Mediated Apoptosis of T Cells Depending on Antigenic Load. <i>Journal of Immunology</i> , 2012, 188, 4256-4267.	0.8	21
58	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4315.	4.1	21
59	Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation. <i>International Immunology</i> , 2002, 14, 973-982.	4.0	20
60	AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 4151-4164.	5.2	20
61	Combined ibrutinib and venetoclax treatment vs single agents in the <i>TCL1</i> mouse model of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2021, 5, 5410-5414.	5.2	20
62	CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. , 2020, 8, e000218.		19
63	Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries. <i>FEBS Letters</i> , 1998, 431, 170-174.	2.8	18
64	Withdrawal symptoms on display: Bcl-2 members under investigation. <i>Trends in Immunology</i> , 2007, 28, 26-32.	6.8	18
65	Viral double-stranded RNA sensors induce antiviral, pro-inflammatory, and pro-apoptotic responses in human renal tubular epithelial cells. <i>Kidney International</i> , 2012, 82, 664-675.	5.2	18
66	The fourth dimension in immunological space: how the struggle for nutrients selects high-affinity lymphocytes. <i>Immunological Reviews</i> , 2012, 249, 84-103.	6.0	18
67	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. <i>Haematologica</i> , 2021, 106, 1234-1243.	3.5	18
68	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. <i>Journal of Immunology</i> , 2019, 203, 2100-2109.	0.8	16
69	Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1849-1853.	1.3	15
70	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 609409.	2.8	15
71	Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. <i>Cell Death and Disease</i> , 2021, 12, 229.	6.3	15
72	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. <i>Cancers</i> , 2021, 13, 284.	3.7	15

#	ARTICLE	IF	CITATIONS
73	Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. <i>HemaSphere</i> , 2019, 3, e308.	2.7	14
74	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. <i>Blood</i> , 2022, 140, 630-643.	1.4	14
75	B-cell antigen receptor-induced apoptosis: looking for clues. <i>Immunology Letters</i> , 2005, 96, 187-194.	2.5	13
76	The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling. <i>Journal of Immunology</i> , 2009, 183, 621-630.	0.8	13
77	Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 126, 512-516.	2.5	12
78	Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling. <i>Scientific Reports</i> , 2016, 6, 35673.	3.3	11
79	CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. <i>Haematologica</i> , 2017, 102, 2069-2076.	3.5	11
80	Human CXCR5 ⁺ PD-1 ⁺ CD8 T cells in healthy individuals and patients with hematologic malignancies. <i>European Journal of Immunology</i> , 2021, 51, 703-713.	2.9	11
81	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. <i>Blood Advances</i> , 2021, 5, 913-925.	5.2	11
82	BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1306-1318.	4.9	10
83	Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. <i>Leukemia</i> , 2022, 36, 2165-2176.	7.2	8
84	Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. <i>British Journal of Haematology</i> , 2014, 167, 565-569.	2.5	7
85	The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7582-TPS7582.	1.6	7
86	Induction of TP73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2439-2447.	1.3	6
87	Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. <i>Haematologica</i> , 2016, 101, e374-e377.	3.5	6
88	Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. <i>Journal of Immunology</i> , 2020, 204, 360-374.	0.8	6
89	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk. <i>Blood</i> , 2013, 122, 4188-4188.	1.4	6
90	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. <i>Cancer Research Communications</i> , 2022, 2, 330-341.	1.7	6

#	ARTICLE	IF	CITATIONS
91	The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 838-847.	0.8	5
92	Effect of oxidative stress on respiratory epithelium from children with Down syndrome. <i>European Respiratory Journal</i> , 2013, 42, 1037-1045.	6.7	5
93	The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. <i>Cell Cycle</i> , 2019, 18, 2307-2322.	2.6	5
94	First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment. <i>Blood</i> , 2018, 132, 1860-1860.	1.4	5
95	SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy. <i>Blood</i> , 2012, 120, 711-711.	1.4	5
96	Redirection of CMV Specific CTL towards B-CLL Via CD20 Targeted HLA/CMV Complexes.. <i>Blood</i> , 2005, 106, 449-449.	1.4	3
97	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. <i>Blood</i> , 2014, 124, 1981-1981.	1.4	3
98	Bcl-2 Members As Drug Target and Biomarkers for Response to Ibrutinib and Venetoclax in CLL. <i>Blood</i> , 2016, 128, 2043-2043.	1.4	3
99	Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax. <i>Blood</i> , 2021, 138, 1545-1545.	1.4	3
100	Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. <i>Leukemia and Lymphoma</i> , 2008, 49, 1592-1602.	1.3	2
101	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. <i>Blood</i> , 2018, 132, 235-235.	1.4	2
102	c-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL.. <i>Blood</i> , 2007, 110, 3078-3078.	1.4	2
103	Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction. <i>Blood</i> , 2012, 120, 3900-3900.	1.4	2
104	A BAFFling <i>–trois</i>; in mantle cell lymphoma. <i>Haematologica</i> , 2022, 107, 2774-2775.	3.5	2
105	Enhanced Formation and Survival of Regulatory T Cells in CLL.. <i>Blood</i> , 2008, 112, 1065-1065.	1.4	1
106	Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. <i>Blood</i> , 2012, 120, 2872-2872.	1.4	1
107	The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial. <i>Blood</i> , 2013, 122, 2861-2861.	1.4	1
108	GSI-1, a Putative Notch Inhibitor, Induces Apoptosis in B-CLL Cells Via Proteasomal Inhibition and Noxa Upregulation.. <i>Blood</i> , 2007, 110, 3113-3113.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1209-1209.	1.4	1
110	Variations of Noxa Levels Caused by p38 MAPK Signaling Result In Heterogeneous Sensitivity to ABT-737 In CD40L-Stimulated CLL Cells. Blood, 2010, 116, 1825-1825.	1.4	1
111	The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study. Blood, 2012, 120, 1798-1798.	1.4	1
112	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform $\hat{\pm}$ and $\hat{\gamma}$ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691.	1.4	1
113	Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 479-479.	1.4	1
114	Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52. Blood, 2021, 138, 3714-3714.	1.4	1
115	Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia. Blood, 2020, 136, 36-37.	1.4	1
116	miR in CLL: more than mere markers of prognosis?. Blood, 2014, 124, 2-4.	1.4	0
117	Autologous CMV-Specific T Cells as Effector Cells in Immunotherapy of B Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2512-2512.	1.4	0
118	The Novel Cancer Drug Seliciclib Engages the Mitochondrial Apoptosis Pathway Via the Mcl-1/Noxa Axis in CLL.. Blood, 2005, 106, 2983-2983.	1.4	0
119	Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.. Blood, 2006, 108, 2103-2103.	1.4	0
120	In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.. Blood, 2007, 110, 1128-1128.	1.4	0
121	Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2008, 112, 2102-2102.	1.4	0
122	R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.. Blood, 2009, 114, 3449-3449.	1.4	0
123	CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism. Blood, 2010, 116, 3979-3979.	1.4	0
124	Role for BH3-Only Protein NOXA In Growth-Factor Deprivation and Early Erythropoiesis. Blood, 2010, 116, 4235-4235.	1.4	0
125	Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,. Blood, 2011, 118, 3871-3871.	1.4	0
126	CMV-Specific CD8+ T-CELL Function Is NOT Impaired In CLL. Blood, 2013, 122, 2862-2862.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Targeting BCR-Independent Proliferation of CLL Cells. <i>Blood</i> , 2015, 126, 2916-2916.	1.4	0
128	CLL Disease Severity Is Enhanced in Tc1 Mice Deficient for Pro-Apoptotic Regulator Noxa. <i>Blood</i> , 2015, 126, 4144-4144.	1.4	0
129	A New Therapeutic Hypothesis: Nonsense-Mediated Decay Is an Exploitable Target in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1937-1937.	1.4	0
130	First Evidence of Dysfunctional Antigen-Specific T Cell Responses in Experimental CLL As a Model for Studies of Autologous T Cell-Based Therapies. <i>Blood</i> , 2018, 132, 3694-3694.	1.4	0
131	Cross-Talk between Cytokine and NF- κ B Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax. <i>Blood</i> , 2019, 134, 5449-5449.	1.4	0
132	CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction. <i>Blood</i> , 2019, 134, 3043-3043.	1.4	0
133	Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance. <i>Blood</i> , 2021, 138, 3717-3717.	1.4	0
134	Development of a Novel Lymph Node-Based 3D Culture System Promoting Chronic Lymphocytic Leukemia Proliferation and Survival. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
135	Electron Transport Chain Inhibition Suppresses CD40 Expression and Sensitizes Chronic Lymphocytic Leukaemia Cells to Venetoclax. <i>Blood</i> , 2020, 136, 35-35.	1.4	0